The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs OC 459 (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Atopix Therapeutics
- 03 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
- 03 Oct 2016 Status changed from not yet recruiting to recruiting.
- 12 Jul 2016 Planned initiation date changed from 1 Oct 2015 to 1 Aug 2015.